Abstract Awards at the 13th Congress of ECCO
Another record number of abstracts has been submitted for the 13th Congress of ECCO. Out of 1,366 submitted scientific abstracts, 1,012 abstracts have been accepted.
Of these abstracts, 38 have been selected as Oral Presentations during the Scientific Programme and another 80 were selected as Digital Oral Presentations. Each of these presentations was reviewed by ECCO Committee Members in order to select the winners of the Top 10 DOPs, IIS Abstract Awards, and the Y-ECCO Abstract Awards.
Top 10 Digital Oral Presentations
DOP009 “Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score-matched analysis”, D. Lukin et al, Montefiore Medical Center, New York, United States
DOP012 “Disease demarcation in Ulcerative Colitis is associated with different patterns of gene expression”, M. Suarez-Farinas et al, Icahn School of Medicine at Mount Sinai, New York, United States
DOP022 “Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trial”, J. E. Kreijne et al, Erasmus MC, Rotterdam, the Netherlands
DOP034“Assessment of direct healthcare cost drivers of Crohn's Disease in a Dutch population-based cohort study shows a major shift”, R. Lalisang et al, Maastricht University Medical Centre +, Maastricht, The Netherlands
DOP039 “Exploring stoma rates in Crohn’s Disease in the biologic era: A population-based time trend analysis”, C. Ma et al, University of Calgary, Calgary, Canada
DOP049 “Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective study”, D. Tarabar et al, Military Medical Academy, Belgrade, Serbia
DOP056 “Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s Disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study”, K. Matsuoka et al, Tokyo Medical and Dental University, Tokyo, Japan
DOP066 “Developing a core outcome set for fistulising perianal Crohn’s Disease”, K. Sahnan et al, St. Mark's Hospital, London, United Kingdom
DOP074 “IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repair”, L. Riccardo Lopetuso et al, Catholic University of Sacred Heart, Rome, Italy
DOP087 “The gut microbiota of pregnant women with Crohn’s Disease and their babies is associated with abnormalities in the adaptive immune system – results from the MECONIUM study”, J. Torres et al, Icahn School of Medicine at Mount Sinai, New York, United States
 Top Ten DOP Winners at ECCO'18, Vienna |
Y-ECCO Abstract Awards
OP002 “Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s Disease cohort shows a quiescent disease course for a substantial proportion of the population”, D. Wintjens et al, Maastricht University Medical Center +, Maastricht, The Netherlands
OP008 “α4β7 integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages”, L. Schleier et al, University of Erlangen-Nuremberg, Erlangen, Germany
OP028 “Single cell RNA sequencing of t-cells in Crohn’s Disease identifies tissue specific drug targets”, E. Festen et al, University Medical Center Groningen, Groningen, The Netherlands
OP032 “Outcome of pregnancies in female IBD patients treated with vedolizumab”, A. Moens et al, University Hospitals Leuven, Leuven, Belgium
OP036 “Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study”, M. de Jong et al, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
IIS Abstract Awards
OP019 “In faecal microbiota transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)”, S. Paramsothy et al, University of New South Wales, Sydney, Australia
OP031 “Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study”, N.A. Kennedy et al, University of Exeter, Exeter, United Kingdom